349 related articles for article (PubMed ID: 8851595)
1. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.
James JK; Palmer SM; Levine DP; Rybak MJ
Antimicrob Agents Chemother; 1996 Mar; 40(3):696-700. PubMed ID: 8851595
[TBL] [Abstract][Full Text] [Related]
2. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
Benko AS; Cappelletty DM; Kruse JA; Rybak MJ
Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594
[TBL] [Abstract][Full Text] [Related]
3. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.
Klepser ME; Patel KB; Nicolau DP; Quintiliani R; Nightingale CH
Pharmacotherapy; 1998; 18(5):1069-74. PubMed ID: 9758317
[TBL] [Abstract][Full Text] [Related]
4. Comparison of vancomycin pharmacodynamics (1 g every 12 or 24 h) against methicillin-resistant staphylococci.
Lacy MK; Tessier PR; Nicolau DP; Nightingale CH; Quintiliani R
Int J Antimicrob Agents; 2000 Jun; 15(1):25-30. PubMed ID: 10856673
[TBL] [Abstract][Full Text] [Related]
5. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species.
DeRyke CA; Sutherland C; Zhang B; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2006 Nov; 50(11):3529-34. PubMed ID: 17065618
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
Waineo MF; Kuhn TC; Brown DL
J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
8. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.
Nicolau DP; Nightingale CH; Banevicius MA; Fu Q; Quintiliani R
Antimicrob Agents Chemother; 1996 Jan; 40(1):61-4. PubMed ID: 8787880
[TBL] [Abstract][Full Text] [Related]
9. Continuous vs. intermittent vancomycin therapy for Gram-positive infections not caused by methicillin-resistant Staphylococcus aureus.
Duszynska W; Taccone FS; Hurkacz M; Wiela-Hojenska A; Kübler A
Minerva Anestesiol; 2016 Mar; 82(3):284-93. PubMed ID: 26184702
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Adane ED; Herald M; Koura F
Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
[TBL] [Abstract][Full Text] [Related]
11. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis.
Fernández de Gatta Mdel M; Santos Buelga D; Sánchez Navarro A; Dominguez-Gil A; García MJ
Clin Pharmacokinet; 2009; 48(4):273-80. PubMed ID: 19492872
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo pharmacokinetics-pharmacodynamics of GV143253A, a novel trinem.
Ferrari L; Iavarone L; Braggio S; Di Modugno E
Antimicrob Agents Chemother; 2003 Feb; 47(2):770-6. PubMed ID: 12543690
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
[TBL] [Abstract][Full Text] [Related]
15. Comparison of continuous infusion versus intermittent infusion of vancomycin in patients with methicillin-resistant Staphylococcus aureus.
Jaruratanasirikul S; Julamanee J; Sudsai T; Saengsuwan P; Jullangkoon M; Ingviya N; Jarumanokul R
J Med Assoc Thai; 2010 Feb; 93(2):172-6. PubMed ID: 20301996
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure.
Hamada Y; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2016 Feb; 60(2):955-61. PubMed ID: 26621619
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.
Nicasio AM; Bulitta JB; Lodise TP; D'Hondt RE; Kulawy R; Louie A; Drusano GL
Antimicrob Agents Chemother; 2012 Feb; 56(2):682-6. PubMed ID: 22083484
[TBL] [Abstract][Full Text] [Related]
18. Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects.
Ampe E; Delaere B; Hecq JD; Tulkens PM; Glupczynski Y
Int J Antimicrob Agents; 2013 May; 41(5):439-46. PubMed ID: 23523733
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.
Kitzis MD; Goldstein FW
Clin Microbiol Infect; 2006 Jan; 12(1):92-5. PubMed ID: 16460555
[TBL] [Abstract][Full Text] [Related]
20. Modified vancomycin dosing protocol for treatment of diabetic foot infections.
Niu SC; Deng ST; Lee MH; Ho C; Chang HY; Liu FH
Am J Health Syst Pharm; 2008 Sep; 65(18):1740-3. PubMed ID: 18769001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
